BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36036240)

  • 1. Correlations between maternal hepatitis B virus carrier status and Down's syndrome prenatal screening indicators and their effects on the screening results.
    Huang L; Chen Y; Ning W; Chen Y; Yu D
    J Obstet Gynaecol; 2022 Oct; 42(7):2793-2798. PubMed ID: 36036240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
    Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012600. PubMed ID: 28295158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First trimester serum tests for Down's syndrome screening.
    Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD011975. PubMed ID: 26617074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
    Spencer K
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
    Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
    Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group.
    Wald NJ; George L; Smith D; Densem JW; Petterson K
    Br J Obstet Gynaecol; 1996 May; 103(5):407-12. PubMed ID: 8624312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness.
    Biagiotti R; Brizzi L; Periti E; d'Agata A; Vanzi E; Cariati E
    Br J Obstet Gynaecol; 1998 Aug; 105(8):917-20. PubMed ID: 9746387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
    Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
    Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of maternal serum for fetal Down's syndrome in the first trimester.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
    N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prenatal Down's syndrome screening at 10-14 weeks gestation using the combined nuchal translucency and maternal serum biochemistry: preliminary results of the first 358 cases].
    Maymon R; Bergman M; Segal S; Dreazen E; Weinraub Z; Herman A
    Harefuah; 2001 Jul; 140(7):594-9, 679. PubMed ID: 11481959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.
    Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012599. PubMed ID: 28295159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies.
    Maymon R; Sharony R; Grinshpun-Cohen J; Itzhaky D; Herman A; Reish O
    J Perinat Med; 2005; 33(5):392-8. PubMed ID: 16238533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
    Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
    Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study.
    Crossley JA; Aitken DA; Cameron AD; McBride E; Connor JM
    BJOG; 2002 Jun; 109(6):667-76. PubMed ID: 12118646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Screening by maternal serum markers for Down's syndrome].
    Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective cohort study on the effects of Down's screening markers and maternal characteristics on pregnancy outcomes in preeclampsia.
    Wu B; Ning W; Chen Y; Wen C; Zhang H; Chen Y
    Clin Exp Hypertens; 2022 Oct; 44(7):610-618. PubMed ID: 35787215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.